Table 1.
ADVANCE Study Eligibility and Completion Rates
| Study Participation Category | N | Percent (of preceding row) |
|---|---|---|
|
| ||
| Total Screened | 1781 | |
|
| ||
| Eligible for ADVANCE Study | 1593 | 89.4 |
|
| ||
| Consented for ADVANCE Study | 1588 | 99.7 |
|
| ||
| Completed HIV Risk Questionnaire | 1588 | 100 |
|
| ||
| Successful Blood Draw | 1566 | 98.6 |
|
| ||
| Notified of Blood Test Results | 1561 | 99.7 |
|
| ||
| Eligible for Follow-up Questionnaire* | 1473 | 94.4 |
|
| ||
| Consented for Follow-up Questionnaire | 1200 | 81.5 |
|
| ||
| Completed Follow-up Questionnaire | 1197 | 99.8 |
|
| ||
|
| ||
| Ineligible | 188 | 10.6† |
|
| ||
| Ineligibility reason‡ | (% of ineligible) | |
| Not biological male | 15§ | 7.9 |
| <18 or >39 years of age | 48|| | 25.5 |
| Zip code ineligible (out of area) | 27 | 14.4 |
| No oral or anal sex with a male past 3 months | 19 | 10.1 |
| Exchanging money or goods for sex past 3 months | 11 | 5.6 |
| IDU past 3 months | 1 | <1 |
| Self-reported HIV-positive | 15 | 8.0 |
| Positive for syphilis past 3 months | 4 | 2.1 |
| Positive for gonorrhea past 3 months | 47 | 25.0 |
| Positive for chlamydia past 3 months | 30 | 16.0 |
| Discontinued eligibility survey | 2¶ | 1.1 |
When data collection started on December 7, 2020, follow-up eligibility was restricted to participants who tested HIV-positive or tested HIV-negative and PrEP-reactive. Starting on May 10, 2021, participants who tested HIV-negative and PrEP negative/inconclusive but who reported any PrEP use in the HIV risk questionnaire became eligible for a follow-up survey. Starting on July 6, 2021, participants who tested HIV-negative and PrEP-negative/-inconclusive and did not report PrEP use in the HIV risk questionnaire also became eligible.
Of all presenting participants.
Respondents may have reported more than one reason for ineligibility; 159 (84.6%) were ineligible for 1 reason, 27 (14.4%) for 2 reasons, and 2 (1.1%) for 3 reasons.
Includes 1 case who declined to answer the question (and was otherwise eligible).
The number of age-ineligible participants (n=48) exceeds what is recorded in Table 2 for <18 and 40+ (n=39), because the upper limit of age eligibility expanded from 30 to 39 on May 10, 2021.
Both participants were males within the eligible age range.